Obe­si­ty drug­mak­er lands first bio­phar­ma up­list­ing on­to Nas­daq since last sum­mer

For the first time since last sum­mer, a biotech has up­list­ed from an over-the-counter stock ex­change to the Nas­daq. Such a move has be­come a rar­i­ty in re­cent years, mir­ror­ing the dif­fi­cul­ty that drug de­vel­op­ers have had in go­ing through ini­tial pub­lic of­fer­ings.

But be­hind the in­dus­try’s first up­list­ing of 2024, from San Diego biotech Skye Bio­science, is in­vestors’ in­ter­est in an area of drug R&D that every ther­a­peu­tics de­vel­op­er wants in on right now: the next wave of obe­si­ty med­ica­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER